Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis
Conditions
- Complicated Urinary Tract Infection
- Pyelonephritis
Interventions
- DRUG: CXA-201
- DRUG: Levofloxacin
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)